Discover a study exploring how GLP-1 receptor agonists may reduce symptoms of hidradenitis suppurativa through weight loss and anti-inflammatory effects.

In the study, 45.2% and 55.0% of patients treated with Upadacitinib 15 mg and 30 mg doses, respectively, reached 80% or more ...

In addition, phase III data with Rinvoq in vitiligo are expected later in 2025, followed by hidradenitis suppurativa and systemic lupus erythematosus Phase III readouts in 2026. AbbVie believes that ...